Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeiq Regulatory News (HEIQ)

  • There is currently no data for HEIQ

Restructuring and Delisting

22 Oct 2024 07:00

RNS Number : 0281J
HeiQ PLC
22 October 2024
 

This announcement contains inside information

 

HeiQ Plc

(the "Company")

Restructuring and Delisting

As detailed in the Company's trading update on 12 September 2024, with the exception of the Life Sciences business unit, the Company continues to face significant challenges in its core business units in Textiles, Flooring, and Antimicrobials due to ongoing curtailed demand. The industry wide consensus is that market conditions are only expected to recover towards the second half of 2025 and accordingly, the Company does not expect to see a significant improvement in performance of these core business units before then. In response, the Company has initiated a second restructuring plan aimed at reducing its costs by up to an additional 20% by the end of 2025. Key elements of this restructuring include:

· Reducing central organisation costs

· Relocating and streamlining of capabilities to hubs in Portugal, USA and Thailand

· Scaling back non-core elements of the Company's innovation pipeline and a reduction of associated corporate marketing activities

The Company has reviewed its strategic product portfolio within its core business units and is considering selective divestments, providing a commercially attractive offer or offers can be achieved. Any proceeds from divestments, should they materialize, would be used to finance HeiQ's three ventures (HeiQ AeoniQ, HeiQ GrapheneX and HeiQ Xpectra) and to accelerate the growth of its Life Sciences business unit.

Fundraising to scale-up Venture Units

· The Company is seeking substantial financing for its HeiQ AeoniQ venture, which, as reported in its recent trading update, recently met a key value-creating milestone by launching to market the world's first AeoniQ plastic-minimized sneaker with Hugo Boss. As previously announced, the Company embarked on a process to raise equity financing exclusively for the HeiQ AeoniQ subsidiary level.

· The Directors believe that the Company is close to meeting key milestones for its other two ventures, HeiQ GrapheneX and HeiQ Xpectra, and plans to accelerate their go-to-market strategies with additional external financing.

The Directors consider that the historically low valuation of HeiQ Plc limits the Company's ability to secure financing at HeiQ Plc level and complicates its efforts to raise funds for the various venture platforms at a subsidiary level.

Delisting

The Directors have concluded that the administrative, regulatory and cost burden associated with maintaining the Company's listing is, in their opinion, disproportionate to the benefits. In order to implement the restructuring programme detailed above, as well as to assist in the Company's financing efforts for its ventures, the Board has therefore concluded that it is necessary to cancel the listing of the Company's ordinary shares (the "Shares") on the Official List (equity shares (transition) category) of the Financial Conduct Authority ("FCA") and to cancel the admission to trading of the Shares on the Main Market for listed securities of the London Stock Exchange ("LSE") (the "Delisting"). The Directors believe that the Delisting would facilitate its restructuring programme, through a major reduction in annualized costs associated with being a listed company. Furthermore, the Directors believe that the Delisting would greatly assist the Company to raise financing in the private markets for its venture platforms at higher valuations and enable their growth and value creation for Company's shareholders.

As a company listed on the equity shares (transition) category, the Company is not required to obtain the approval of shareholders for the Delisting but is required under UK Listing Rule 21.2.17 to give at least 20 business days' notice of the intended cancellation.

Accordingly, HeiQ has requested that (i) the FCA cancel the listing of the Shares on the Official List of the FCA, and that (ii) the LSE cancels the admission to trading of the Shares on the Main Market for listed securities of the LSE. It is anticipated that the Delisting will become effective from 08:00 a.m. (London time) on 19 November 2024. Investors holding Shares following the Delisting will remain a shareholder of HeiQ plc and continue to be entitled to exercise all of the rights attaching to the Shares and their attention is drawn to the paragraph below entitled "Dealing Arrangements",

The Company intends to publish its Annual Accounts for the 18-month period ending 30 June 2024 by 31 October 2024, as required by the UK Listing Rules. The Company's 2024 Annual General Meeting is expected to take place in November 2024, further details of which will be announced in due course.

Dealing Arrangements

Following the Delisting, the Shares will be admitted to trading on the JP Jenkins securities matching platform with effect from 20 November 2024.

JP Jenkins provides a securities matching venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell shares on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).

Shareholders wishing to trade Shares on the JP Jenkins platform can place orders through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.

The indicative pricing for the ordinary Shares (ISIN: GB00BN2CJ299), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/HeiQ/).

The provision of the matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, the composition of the Company's register of members and the associated costs to the Company and its shareholders.

For further information, please contact: investors@heiq.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDFLFLZBLZFBV
Date   Source Headline
2nd Dec 20227:00 amRNSAcquisition of Chem-Tex Laboratories, Inc
7th Nov 20227:00 amRNSChange of Auditor
10th Oct 20227:00 amRNSFiles Breach of Exclusive Agreement Complaint
13th Sep 20227:00 amRNSInterim Results
30th Aug 20227:00 amRNSNotice of H1 2022 Results and Presentation
8th Aug 202210:33 amRNSIssue of Equity and Total Voting Rights
29th Jun 202211:06 amRNSResult of AGM
14th Jun 20227:00 amRNSCommercial progress of HeiQ’s Hygiene technologies
18th May 20227:00 amRNSNotice of AGM
12th May 20227:00 amRNSPayment of Earnout Consideration
28th Apr 20227:00 amRNSResults for the year ended 31 December 2021
14th Apr 20227:00 amRNSFY 2021 Trading Update and Notice of Results
24th Feb 20222:55 pmRNSIssue of Equity
17th Feb 20222:35 pmRNSDirector/PDMR Shareholding
14th Feb 20227:00 amRNSHUGO BOSS and LYCRA back new climate positive yarn
3rd Dec 20217:00 amRNSInvestor Presentation
28th Sep 20219:05 amRNSSecond Price Monitoring Extn
28th Sep 20219:00 amRNSPrice Monitoring Extension
28th Sep 20217:00 amRNSInterim Results
20th Sep 20217:00 amRNSNotice of Results and Investor Presentation
16th Jul 20217:00 amRNSCollaboration Agreement with The LYCRA Company
9th Jul 20217:00 amRNSCompletion of Acquisition
28th Jun 20211:45 pmRNSFurther re. Annual General Meeting
25th Jun 20214:40 pmRNSResult of AGM
21st Jun 20214:30 pmRNSAnnual General Meeting Update
15th Jun 20217:00 amRNSAcquisition Life Material Technologies Limited
9th Jun 20217:00 amRNSHeiQ Chrisal water treatment solution contract win
28th May 20217:00 amRNSCreates sustainable textile finishing partnership
20th May 20214:20 pmRNSProgressive initiates coverage
13th May 20217:00 amRNSNotice of AGM
29th Apr 20217:00 amRNSAcquisition of RAS AG
28th Apr 20217:00 amRNSResults for the year ended December 31, 2020
8th Apr 20217:00 amRNSNotice of Results and Investor Presentation
19th Mar 20217:00 amRNSHeiQ Viroblock Agreement with ICP
11th Mar 20217:00 amRNSHeiQ Viroblock Partnership with Berger Paint
3rd Mar 20217:00 amRNSAcquisition of 51% of Industrial Biotech Business
11th Feb 20217:00 amRNSHeiQ Viroblock Contract Win
28th Jan 202111:30 amRNSLaunch of HeiQ Viroblock Permanent
27th Jan 20219:05 amRNSSecond Price Monitoring Extn
27th Jan 20219:00 amRNSPrice Monitoring Extension
26th Jan 20219:05 amRNSSecond Price Monitoring Extn
26th Jan 20219:00 amRNSPrice Monitoring Extension
26th Jan 20217:00 amRNSTrading Update
13th Jan 20217:00 amRNSChange of External Auditor
5th Jan 20212:01 pmRNSPrice Monitoring Extension
4th Jan 20219:05 amRNSSecond Price Monitoring Extn
4th Jan 20219:00 amRNSPrice Monitoring Extension
15th Dec 20207:00 amRNSMajority stake in medical device manufacturer
9th Dec 202011:15 amRNSDirector/PDMR Dealings
9th Dec 20207:00 amRNSInvestor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.